TEL AVIV, Israel, Feb. 1, 2018 /PRNewswire/ --
Summary of Highlights
Capital raising will support the company's clinical and strategic goals
About the Company
Cellect Biotechnology Ltd. (NASDAQ:APOP) (hereinafter "Cellect" or "the company") focuses on the development of a technological platform (the ApoGraft™) which selectively isolates stem cells from a mixed population of cells based on their unique sensitivity to apoptosis. The first product under development is the Apotainer selection kit. The company is currently conducting a proof-of-concept phase I/II clinical trial with leukemia patients in Israel, which is expected to be completed by the end of Q3 2018. Pending positive trial results and ensuring sufficient information is gathered to support adequate safety profiles, the company plans to integrate its technology across a range of procedures that utilize stem cells. They can as well use this platform for the manufacturing of adult stem cells. Please click here.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.
For further information, please contact:
Kristi CekaniCorporate Communications - Frost & Sullivan, Europe P: +39.02.4851.6133E: Kristi.email@example.com http://www.frost.com
View original content:http://www.prnewswire.com/news-releases/frost--sullivan-publishes-an-update-report-on-cellect-biotechnology-ltd-capital-raising-of-4m-will-support-the-companys-clinical-and-strategic-goals-price-target-unchanged-300592070.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!